Adacel

Adacel is a brand name for the drug adalimumab, which is a monoclonal antibody used to treat various autoimmune diseases. It is manufactured by AbbVie, a global biopharmaceutical company. Adalimumab works by targeting and blocking a protein called tumor necrosis factor-alpha (TNF-alpha), which plays a key role in the inflammatory response. By inhibiting TNF-alpha, Adacel helps to reduce inflammation and symptoms in conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis.

Adacel is administered through subcutaneous injection, typically every other week or every two weeks, depending on the specific condition being treated. The dosage and frequency of administration may vary based on the patient's response to the treatment and the severity of their condition. Common side effects of Adacel include injection site reactions, upper respiratory tract infections, and increased risk of infections.

Adacel has been approved by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of the aforementioned conditions. It is available in various countries under different brand names, including Humira in the United States and Canada, and Enbrel in many other countries. Adacel is often used as a first-line treatment for moderate to severe rheumatoid arthritis and psoriatic arthritis, as well as for Crohn's disease and ulcerative colitis.

Adacel is not recommended for use in patients with an active infection, such as tuberculosis, or those with a history of tuberculosis. It should also be used with caution in patients with a history of demyelinating diseases, such as multiple sclerosis, and in those with a history of lymphoma or other cancers. As with any medication, Adacel carries potential risks and side effects, and it is important for patients to discuss the benefits and risks with their healthcare provider before starting treatment.